FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Veerle Kersemans

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Tumor Cell Line

Concepts & Ideas

Tissue Distribution

Procedures

Single-Photon Emission-Computed Tomography

Physiology

Organ Specificity

Phenomena

Metabolic Clearance Rate

Disorders

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Bart Cornelissen; Alison Crossley; Kerstin Jurkshat; Veerle Kersemans; Sverre Myhra; Sarah Able; Philip A Waghorn; Katherine A Vallis
Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors.
Chad M McKee; Michael Milosevic; Melania Pintile; Varune Rohan Ramnarine; Sean Smart; Jenna Sykes; Theodorus van der Kwast; Danmei Xu; Gaetano Zafarana; Danny Allen; John Beech; Robert G Bristow; Yunhong Cao; Freddie Hamdy; Adrian Ishkanian; Igor Jurisica; Sheheryar Kabraji; Veerle Kersemans; Wan Lam; Chad Mallof; Ruth J Muschel
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
Bart Cornelissen; Sonali Darbar; Nadia Falzone; Veerle Kersemans; Sean Smart; Danny Allen; Jody Barbeau; Katherine A Vallis
Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Veerle Kersemans (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Bart Cornelissen; Alison Crossley; Kerstin Jurkshat; Veerle Kersemans; Sverre Myhra; Sarah Able; Philip A Waghorn; Katherine A Vallis
Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors.
Biomaterials 2013;34(4):1146-54.
2012: Chad M McKee; Michael Milosevic; Melania Pintile; Varune Rohan Ramnarine; Sean Smart; Jenna Sykes; Theodorus van der Kwast; Danmei Xu; Gaetano Zafarana; Danny Allen; John Beech; Robert G Bristow; Yunhong Cao; Freddie Hamdy; Adrian Ishkanian; Igor Jurisica; Sheheryar Kabraji; Veerle Kersemans; Wan Lam; Chad Mallof; Ruth J Muschel
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.
The Journal of clinical investigation 2012;122(11):4025-36.
2012: Bart Cornelissen; Sonali Darbar; Nadia Falzone; Veerle Kersemans; Sean Smart; Danny Allen; Jody Barbeau; Katherine A Vallis
Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
Nuclear medicine and biology 2012;39(8):1142-51.
2012: Bart Cornelissen; Veerle Kersemans; Sean Smart; Carol Target; Andrew Waller; Katherine A Vallis
111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
EJNMMI research 2012;2():9.
2011: Veerle Kersemans; Ruth J Muschel; James Thompson; Michael Woodcock; Philip D Allen; Nico Buls; Bart Cornelissen; Mark A Hill; Sean C Smart
Micro-CT for anatomic referencing in PET and SPECT: radiation dose, biologic damage, and image quality.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(11):1827-33.
2011: Bart Cornelissen; Sonali Darbar; Mark A Hill; Veerle Kersemans; Ketan Shah; Kate Sleeth; James Thompson; Katherine A Vallis
Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates.
Cancer research 2011;71(13):4539-49.
2011: Bart Cornelissen; Sonali Darbar; Rebecca Hernandez; Veerle Kersemans; Iain Tullis; Paul Richard Barber; Sean Smart; Borivoj Vojnovic; Raymond Reilly; Katherine A Vallis
ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(5):776-83.
2011: Veerle Kersemans; Ruth J Muschel; Matthew Tredwell; Philip D Allen; Bart Cornelissen; Jonathan R Dilworth; Nadia Falzone; Véronique Gouverneur; Sally A Hill; Rebekka Hueting; Kamila Hussien; Sean C Smart
Hypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.
PloS one 2011;6(11):e25911.
2010: Romain Bejot; Veerle Kersemans; Catherine Kelly; Laurence Carroll; Robert C King; Véronique Gouverneur; Arkadij M Elizarov; Carroll Ball; Jianzhong Zhang; Reza Miraghaie; Hartmuth C Kolb; Sean Smart; Sally Hill
Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET.
Nuclear medicine and biology 2010;37(5):565-75.
2009: Bart Cornelissen; Veerle Kersemans; Kristin McLarty; Lara Tran; Katherine A Vallis; Raymond M Reilly
In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
Nuclear medicine and biology 2009;36(7):811-9.
2009: Bart Cornelissen; Veerle Kersemans; Kristin McLarty; Lara Tran; Raymond M Reilly
111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
Cancer biotherapy & radiopharmaceuticals 2009;24(2):163-73.
2008: Veerle Kersemans; Bart Cornelissen; Mark D Minden; Joseph Brandwein; Raymond M Reilly
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(9):1546-54.
2008: Bart Cornelissen; Kristin McLarty; Veerle Kersemans; Raymond M Reilly
The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Nuclear medicine and biology 2008;35(6):645-53.
2008: Veerle Kersemans; Valentijn G.L.P. Vergote; Virginie de Gelder; Indira Madani; Hubert Thierens; Wilfried De Neve; John Mertens; Guido Slegers; Christian Burvenich; Kathelijne Peremans; Bart De Spiegeleer
The use of [123I]-2-iodo-L-phenylalanine as an early radiotherapy evaluation tool: in vitro R1M rabdomyosarcoma cell and in vivo mouse experiments.
Cancer biotherapy & radiopharmaceuticals 2008;23(2):192-201.
2008: Veerle Kersemans; Ken Kersemans; Bart Cornelissen
Cell penetrating peptides for in vivo molecular imaging applications.
Current pharmaceutical design 2008;14(24):2415-47.
2008: Bart Cornelissen; Kristin McLarty; Veerle Kersemans; Deborah A Scollard; Raymond M Reilly
Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
Nuclear medicine and biology 2008;35(1):101-10.
2007: Kathelijne Peremans; Veerle Kersemans; Tiziana Liuti; E Vandermeulen; Bart Cornelissen; Ingrid M Gielen; Bart De Spiegeleer; John Mertens; Christian Burvenich; Guido Slegers
Use of [123I]-2-iodo-L-phenylalanine as a tumor imaging agent in two dogs with synovial cell sarcoma.
Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association 2007;48(5):471-4.
2006: Veerle Kersemans; Bart Cornelissen; Ken Kersemans; Matthias Bauwens; Rudi A Dierckx; Bart De Spiegeleer; John Mertens; Guido Slegers
123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.
European journal of nuclear medicine and molecular imaging 2006;33(8):919-27.
2006: Veerle Kersemans; Ken Kersemans; Bart Cornelissen; Ludovicus Staelens; Bart De Spiegeleer; John Mertens; Guido Slegers
Optimization by experimental design of precursor synthesis and radiolabeling of 2-iodo-L-phenylalanine, a novel amino acid for tumor imaging.
Cancer biotherapy & radiopharmaceuticals 2006;21(3):235-42.
2006: Ruth Oltenfreiter; Ludovicus Staelens; Veerle Kersemans; Bart Cornelissen; Francis Frankenne; Jean-Michel Foidart; Christophe Van De Wiele; Guido Slegers
Valine-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumor imaging agents.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2006;64(6):677-85.
2006: Veerle Kersemans; Bart De Spiegeleer; John Mertens; Guido Slegers
Influence of sedation and data acquisition method on tracer uptake in animal models: [123I]-2-iodo-L-phenylalanine in pentobarbital-sedated tumor-bearing athymic mice.
Nuclear medicine and biology 2006;33(1):119-23.
2006: Veerle Kersemans; Bart Cornelissen; Ken Kersemans; Rudi A Dierckx; Bart De Spiegeleer; John Mertens; Guido Slegers
Comparative biodistribution study of the new tumor tracer [123I]-2-iodo-L-phenylalanine with [123I]-2-iodo-L-tyrosine.
Nuclear medicine and biology 2006;33(1):111-7.
2005: Ruth Oltenfreiter; Ludovicus Staelens; Soraya Labied; Veerle Kersemans; Francis Frankenne; Agnès Noël; Christophe Van De Wiele; Guido Slegers
Tryptophane-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents.
Cancer biotherapy & radiopharmaceuticals 2005;20(6):639-47.
2005: Veerle Kersemans; Bart Cornelissen; Klaus Bacher; Ken Kersemans; Hubert Thierens; Rudi A Dierckx; Bart De Spiegeleer; Guido Slegers; John Mertens
In vivo evaluation and dosimetry of 123I-2-iodo-D-phenylalanine, a new potential tumor-specific tracer for SPECT, in an R1M rhabdomyosarcoma athymic mouse model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(12):2104-11.
2005: Hilde Laeremans; Heidi Demaegdt; Jean-Paul De Backer; Minh Tam Le; Veerle Kersemans; Yvette Michotte; Georges Vauquelin; Patrick M L Vanderheyden
Metal ion modulation of cystinyl aminopeptidase.
The Biochemical journal 2005;390(Pt 1):351-7.
2005: Bart Cornelissen; Ruth Oltenfreiter; Veerle Kersemans; Ludovicus Staelens; Francis Frankenne; Jean-Michel Foidart; Guido Slegers
In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker.
Nuclear medicine and biology 2005;32(5):431-6.
2005: Ludovicus Staelens; Ruth Oltenfreiter; Peter Blanckaert; Veerle Kersemans; Katia Vandenbulcke; Christophe Van De Wiele; Guido Slegers
In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies.
Nuclear medicine and biology 2005;32(3):293-9.
2005: Bart Cornelissen; Christophe Lahorte; Veerle Kersemans; Gabriela Capriotti; Elena Bonanno; Alberto Signore; Christophe Van De Wiele; Rudi A Dierckx; Guido Slegers
In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
Nuclear medicine and biology 2005;32(3):233-9.
2005: Bart Cornelissen; Veerle Kersemans; L Jans; Ludovicus Staelens; Ruth Oltenfreiter; Thomas Thonissen; Eric Achten; Guido Slegers
Comparison between 1 T MRI and non-MRI based volumetry in inoculated tumours in mice.
The British journal of radiology 2005;78(928):338-42.
2005: Veerle Kersemans; Bart Cornelissen; Ken Kersemans; Matthias Bauwens; Eric Achten; Rudi A Dierckx; John Mertens; Guido Slegers
In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(3):532-9.
2005: Bart Cornelissen; Veerle Kersemans; Ingrid Burvenich; Ruth Oltenfreiter; Jean-Luc Vanderheyden; Otto Boerman; Christophe Vandewiele; Guido Slegers
Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.
Nuclear medicine communications 2005;26(2):147-53.
2004: Heidi Demaegdt; Hilde Laeremans; Jean-Paul De Backer; Sabrina Mosselmans; Minh Tam Le; Veerle Kersemans; Yvette Michotte; Georges Vauquelin; Patrick M L Vanderheyden
Synergistic modulation of cystinyl aminopeptidase by divalent cation chelators.
Biochemical pharmacology 2004;68(5):893-900.
2004: Heidi Demaegdt; Patrick M L Vanderheyden; Jean-Paul De Backer; Sabrina Mosselmans; Hilde Laeremans; Minh Tam Le; Veerle Kersemans; Yvette Michotte; Georges Vauquelin
Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity.
Biochemical pharmacology 2004;68(5):885-92.
2004: John Mertens; Veerle Kersemans; Matthias Bauwens; C Joos; Tony Lahoutte; Axel Bossuyt; Guido Slegers
Synthesis, radiosynthesis, and in vitro characterization of [125I]-2- iodo-L-phenylalanine in a R1M rhabdomyosarcoma cell model as a new potential tumor tracer for SPECT.
Nuclear medicine and biology 2004;31(6):739-46.
2004: Bart Cornelissen; Thomas Thonissen; Veerle Kersemans; Christophe Van De Wiele; Christophe Lahorte; Rudi A Dierckx; Guido Slegers
Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.
Nuclear medicine and biology 2004;31(6):679-89.
2003: Minh Tam Le; Patrick M L Vanderheyden; Márta Szaszák; László Hunyady; Veerle Kersemans; Georges Vauquelin
Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
Biochemical pharmacology 2003;65(8):1329-38.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.